Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26.

[1]  Xinguo Jiang,et al.  Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[2]  H. Gendelman,et al.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. , 2007, Progress in polymer science.

[3]  Michael L Klein,et al.  Emerging Applications of Polymersomes in Delivery: from Molecular Dynamics to Shrinkage of Tumors. , 2007, Progress in polymer science.

[4]  M. Ricci,et al.  Solid lipid nanoparticles for targeted brain drug delivery. , 2007, Advanced drug delivery reviews.

[5]  Xinguo Jiang,et al.  Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[6]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[7]  Raoul Kopelman,et al.  Brain cancer diagnosis and therapy with nanoplatforms. , 2006, Advanced drug delivery reviews.

[8]  Wei Yang Lu,et al.  Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice , 2006, Behavioural Brain Research.

[9]  W. Pardridge.  Molecular Trojan horses for blood-brain barrier drug delivery. , 2006, Discovery medicine.

[10]  D. Hammer,et al.  Bioresorbable Vesicles Formed through Spontaneous Self-Assembly of Amphiphilic Poly(ethylene oxide)-block-polycaprolactone. , 2006, Macromolecules.

[11]  Yan Zhang,et al.  Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Kurachi,et al.  NC-1900, an arginine–vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: Therapeutic implications for schizophrenia , 2005, Brain Research.

[13]  Fenghua Meng,et al.  Biodegradable polymersomes as a basis for artificial cells: encapsulation, release and targeting. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Dennis E Discher,et al.  Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[15]  H. Lee,et al.  Synthesis of Pegylated Immunonanoparticles , 2002, Pharmaceutical Research.

[16]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[17]  Jayanth Panyam,et al.  Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. , 2003, International journal of pharmaceutics.

[18]  F. Bates,et al.  Polymer vesicles in vivo: correlations with PEG molecular weight. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[19]  K. Abe,et al.  Ameliorative effect of NC-1900, a new AVP4–9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze , 2003, Neuropharmacology.

[20]  Dennis E. Discher,et al.  Polymer Vesicles , 2022 .

[21]  V. Labhasetwar,et al.  Characterization of nanoparticle uptake by endothelial cells. , 2002, International journal of pharmaceutics.

[22]  T. Ono,et al.  Effects of a novel arginine-vasopressin derivative, NC-1900, on the spatial memory impairment of rats with transient forebrain ischemia. , 2002, Brain research. Cognitive brain research.

[23]  W. Pardridge,et al.  Drug and gene targeting to the brain with molecular trojan horses , 2002, Nature Reviews Drug Discovery.

[24]  U. Pennsylvania,et al.  Molecular Weight Dependence of Polymersome Membrane Structure, Elasticity, and Stability , 2001, cond-mat/0110088.

[25]  Dennis E. Discher,et al.  Polymer vesicles : Materials science: Soft surfaces , 2002 .

[26]  W. Pardridge.  Brain Drug Targeting: The Future of Brain Drug Development , 2001 .

[27]  U. Bickel,et al.  Delivery of peptides and proteins through the blood-brain barrier. , 1993, Advanced drug delivery reviews.

[28]  Xiaohong Li,et al.  Polymerization of Lactides and Lactones. 10. Synthesis, Characterization, and Application of Amino-Terminated Poly(ethylene glycol)-co-poly(ε-caprolactone) Block Copolymer , 2000 .

[29]  D. Hammer,et al.  Polymersomes: tough vesicles made from diblock copolymers. , 1999, Science.

[30]  D. Devine,et al.  Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. , 1998, Archives of biochemistry and biophysics.

[31]  T. Kameyama,et al.  NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats. , 1998, European journal of pharmacology.

[32]  Amarnath Sharma,et al.  Liposomes in drug delivery: Progress and limitations , 1997 .

[33]  Robert Langer,et al.  PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation of their drug encapsulation and release characteristics1 , 1997 .

[34]  Y. Nakajima,et al.  No. 302, a newly synthesized [pGlu4,Cyt6] AVP(4–9) analogue, prevents the disruption of avoidance behavior , 1997, Behavioural Brain Research.

[35]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  U. Bickel,et al.  Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[37]  W. Pardridge,et al.  Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.

[38]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.